{
    "Trade/Device Name(s)": [
        "Optilite Hevylite IgG Kappa Kit",
        "Optilite Hevylite IgG Lambda Kit"
    ],
    "Submitter Information": "The Binding Site Group Ltd.",
    "510(k) Number": "K172613",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132555"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PCN",
        "PCO"
    ],
    "Summary Letter Date": "August 16, 2017",
    "Summary Letter Received Date": "August 31, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgG Kappa",
        "IgG Lambda"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Binding Site Optilite analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetry"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Optilite Hevylite IgG Kappa and Lambda Kits, quantitative serum immunoassays for monitoring previously diagnosed IgG multiple myeloma using turbidimetry on the Optilite analyser.",
    "Indications for Use Summary": "Quantitative in vitro assays for measuring IgG Kappa and IgG Lambda in serum to calculate the IgG Kappa/IgG Lambda ratio for monitoring previously diagnosed IgG multiple myeloma patients, used in conjunction with other laboratory tests and clinical evaluations.",
    "fda_folder": "Immunology"
}